- Previous Close
156.28 - Open
156.48 - Bid 159.75 x 800
- Ask 160.00 x 800
- Day's Range
156.00 - 160.57 - 52 Week Range
143.13 - 175.97 - Volume
8,063,092 - Avg. Volume
7,226,265 - Market Cap (intraday)
384.202B - Beta (5Y Monthly) 0.52
- PE Ratio (TTM)
23.93 - EPS (TTM)
6.67 - Earnings Date Oct 15, 2024
- Forward Dividend & Yield 4.96 (3.17%)
- Ex-Dividend Date Aug 27, 2024
- 1y Target Est
171.47
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
www.jnj.com131,900
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: JNJ
View More
Performance Overview: JNJ
Trailing total returns as of 7/25/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: JNJ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: JNJ
View MoreValuation Measures
Market Cap
376.12B
Enterprise Value
383.53B
Trailing P/E
23.90
Forward P/E
15.55
PEG Ratio (5yr expected)
0.99
Price/Sales (ttm)
4.88
Price/Book (mrq)
5.37
Enterprise Value/Revenue
4.87
Enterprise Value/EBITDA
17.61
Financial Highlights
Profitability and Income Statement
Profit Margin
43.91%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
86.58B
Net Income Avi to Common (ttm)
16.38B
Diluted EPS (ttm)
6.67
Balance Sheet and Cash Flow
Total Cash (mrq)
26.22B
Total Debt/Equity (mrq)
48.03%
Levered Free Cash Flow (ttm)
--
Research Analysis: JNJ
View MoreCompany Insights: JNJ
JNJ does not have Company Insights
Research Reports: JNJ
View MoreThe Argus Min Vol Model Portfolio
Rapidly rising inflation in 2022 knocked stocks into a bear market. While growth strategies suffered the most, value strategies also declined. Even bond prices were lower that year. Stocks have recovered and a new bull market has started, but gains have been largely driven by only a handful of high-tech companies. Inflation remains an issue and the Federal Reserve has yet to lower rates. Is a recession in the offing? With all the uncertainty, what's a potential equity strategy for investors amid all the uncertainty? Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate. Academic literature and, more to the point, returns history, indicate that Min Vol can deliver market-matching returns on an absolute basis and superior returns on a risk-adjusted basis over various time periods.
The Argus Min Vol Model Portfolio
Rapidly rising inflation in 2022 knocked stocks into a bear market. While growth strategies suffered the most, value strategies also declined. Even bond prices were lower that year. Stocks have recovered and a new bull market has started, but gains have been largely driven by only a handful of high-tech companies. Inflation remains an issue and the Federal Reserve has yet to lower rates. Is a recession in the offing? With all the uncertainty, what's a potential equity strategy for investors amid all the uncertainty? Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate. Academic literature and, more to the point, returns history, indicate that Min Vol can deliver market-matching returns on an absolute basis and superior returns on a risk-adjusted basis over various time periods.
Johnson & Johnson Earnings: Largely in Line as New Products Ready to Offset Stelara Biosimilars
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
RatingPrice TargetNew products and M&A drive 2024 growth
Johnson & Johnson is a diversified global healthcare company that develops, manufactures and markets products in two business segments: Innovative Medicine (formerly Pharmaceuticals) and MedTech.
RatingPrice Target